SukumaranNair S, Lenihan CR, Montez-Rath ME, Lowenberg DW, Chertow GM, Winkelmayer WC: Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. AmJ Transplant 14: 943-951, 2014
Malluche HH, Monier-Faugere M-C, Herberth J: Bone disease after renal transplantation. Nat Rev Nephrol 6: 32-40, 2010
Brandenburg VM, Politt D, Ketteler M, Fassbender WJ, Heussen N, Westenfeld R, Freuding T, Floege J, Ittel TH: Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 77: 1566-1571, 2004
Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E: Bone disease after renal transplantation. Clin J Am Soc Nephrol 1: 1300-1313, 2006
Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N: Risk of fractures after renal transplantation in the United States. Transplantation 87: 1846-1851, 2009
Naylor KL, Li AH, Lam NN, Hodsman AB, Jamal SA, Garg AX:Fracture risk in kidney transplant recipients: A systematic review. Transplantation 95: 1461-1470, 2013
Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C: Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288: 3014-3018, 2002
Nikkel LE, Iyer SP, Mohan S, Zhang A, McMahon DJ, Tanriover B, Cohen DJ, Ratner L, Hollenbeak CS, Rubin MR, Shane E, Nickolas TL; CURE Group (The Columbia University Renal Epidemiology Group): Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes. Kidney Int 83: 471-478, 2013
Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S: In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29: 787-795, 2014
Nikkel LE, Mohan S, Zhang A, McMahon DJ, Boutroy S, Dube G, Tanriover B, Cohen D, Ratner L, Hollenbeak CS, Leonard MB, Shane E, Nickolas TL: Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant 12: 649-659, 2012
Ferro CJ, Arnold J, Bagnall D, Ray D, Sharif A: Fracture risk and mortality post-kidney transplantation. Clin Transplant 29: 1004-1012, 2015
Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093-1099, 2000
Malluche HH, Mawad HW, Monier-Faugere M-C: Renal osteodystrophy in the first decade of the new millennium:Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26: 1368-1376, 2011
Neves CL, dos Reis LM, Batista DG, Custodio MR, Graciolli FG, Martin RC, Neves KR, Dominguez WV, Moyses RM, Jorgetti V: Persistence of bone andmineral disorders 2 years after successful kidney transplantation. Transplantation 96: 290-296, 2013
Cruz EAS, Lugon JR, Jorgetti V, Draibe SA, Carvalho AB: Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis 44: 747-756, 2004
Lehmann G, Ott U, Stein G, Steiner T, Wolf G: Renal osteodystrophy after successful renal transplantation: A histomorphometric analysis in 57 patients. Transplant Proc 39: 3153-3158, 2007
Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD: Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325: 544-550, 1991
Iyer SP, Nikkel LE, Nishiyama KK, Dworakowski E, Cremers S, Zhang C, McMahon DJ, Boutroy S, Liu XS, Ratner LE, Cohen DJ, Guo XE, Shane E, Nickolas TL: Kidney transplantation with early corticosteroid withdrawal: Paradoxical effects at the central and peripheral skeleton. J Am Soc Nephrol 25: 1331-1341, 2014
Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R, Chen H: How well does renal transplantation cure hyperparathyroidism? Ann Surg 262: 653-659, 2015
Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F: A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 100: 184-193, 2016
Akaberi S, Lindergård B, Simonsen O, Nyberg G: Impact of parathyroid hormone on bone density in long-term renal transplant patients with good graft function. Transplantation 82: 749-752, 2006
Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, Muller C, Olagne J, Moulin B: Persistent hyperparathyroidismis a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 13: 2653-2663, 2013
McGregor R, Li G, Penny H, Lombardi G, Afzali B, Goldsmith DJ: Vitamin D in renal transplantation - from biological mechanisms to clinical benefits. Am J Transplant 14: 1259-1270, 2014
Lee JR, Dadhania D, August P, Lee JB, Suthanthiran M, Muthukumar T: Circulating levels of 25-hydroxyvitamin D and acute cellular rejection in kidney allograft recipients. Transplantation 98: 292-299, 2014
Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, Noël LH, Friedlander G, Elie C, Legendre C, Prié D: Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 24: 831-841, 2013
Thiem U, Heinze G, Segel R, Perkmann T, Kainberger F, Mühlbacher F, Hörl W, Borchhardt K: VITA-D: Cholecalciferol substitution in vitaminDdeficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome. Trials 10: 36, 2009
Akaberi S, Simonsen O, Lindergård B, Nyberg G: Can DXA predict fractures in renal transplant patients? Am J Transplant 8: 2647-2651, 2008
Nishiyama KK, Pauchard Y, Nikkel LE, Iyer S, Zhang C, McMahon DJ, Cohen D, Boyd SK, Shane E, Nickolas TL: Longitudinal HR-pQCT and image registration detects endocortical bone loss in kidney transplantation patients. J BoneMiner Res 30: 554-561, 2015
Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
Ing SW, Sinnott LT, Donepudi S, Davies EA, Pelletier RP, Lane NE: Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients. Clin Transplant 25: E113-E123, 2011
Farmer CKT, Hampson G, Abbs IC, Hilton RM, Koffman CG, Fogelman I, Sacks SH: Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant 6: 2929-2936, 2006
Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, Heilman RL, Mazur MJ, Hamawi K, Larson TS, Kumar R:Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism:Results of an open label randomized trial.Am J Transplant 13: 1576-1585, 2013
Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N: Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 26: 1205-1214, 2015
Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, Rutkowski B, Schaefer H, Deng H, Torregrosa JV, Wuthrich RP, Yue S: A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 14: 2545-2555, 2014
Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D: Cinacalcet treatment of primary hyperparathyroidism:Biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 94: 4860-4867, 2009
Courbebaisse M, Diet C, Timsit M-O, Mamzer M-F, Thervet E, Noel L-H, Legendre C, Friedlander G, Martinez F, Prié D: Effects of cinacalcet in renal transplant patients with hyperparathyroidism. Am J Nephrol 35: 341-348, 2012
Borchhardt KA, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G: Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 31: 482-489, 2010
Parikh S, Nagaraja H, Agarwal A, Samavedi S, Von Visger J, Nori U, Andreoni K, Pesavento T, Singh N: Impact of post-kidney transplant parathyroidectomy on allograft function. Clin Transplant 27: 397-402, 2013
Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, Haas M: Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 8: 1864-1870, 2008
Kovac D, Lindic J, Kandus A, Bren AF: Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 70: 1542-1543, 2000
Giannini S, D’Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, DalleCarbonare L, Sartori L, Crepaldi G: Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16: 2111-2117, 2001
Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC: Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12: 1530-1537, 2001
Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN:Prevalence and treatment of decreased bone density in renal transplant recipients: A randomized prospective trial of calcitriol versus alendronate. Transplantation 76: 1498-1502, 2003
Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R: Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63: 1130-1136, 2003
Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H: Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14: 2669-2676, 2003
Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R: Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 65: 304-309, 2004
Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J: Effect of pamidronate on bone loss after kidney transplantation: A randomized trial. AmJ KidneyDis 53: 856-865, 2009
Torregrosa J-V, Fuster D, GentilM-A, Marcen R, Guirado L, Zarraga S, Bravo J, Burgos D, Monegal A, Muxí A, García S: Open-label trial: Effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation 89: 1476-1481, 2010
Torregrosa J-V, Fuster D, Monegal A, Gentil MA, Bravo J, Guirado L, Muxí A, Cubero J: Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant. Osteoporos Int 22: 281-287, 2011
Smerud KT, Dolgos S, Olsen IC, Åsberg A, Sagedal S, Reisæter AV, Midtvedt K, Pfeffer P, Ueland T, Godang K, Bollerslev J, Hartmann A: A 1-year randomized, doubleblind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant 12: 3316-3325, 2012
Coco M, Pullman J, Cohen HW, Lee S, Shapiro C, Solorzano C, Greenstein S, Glicklich D: Effect of risedronate on bone in renal transplant recipients. J Am SocNephrol 23: 1426-1437, 2012
Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 1829-1835, 2011
